Arena Pharma, Inc. (ARNA) announced that it has completed an underwritten public offering of 12.7 million shares of its common stock, including 1.7 million shares sold pursuant to the full exercise of an over-allotment option previously granted to the underwriters.
The company stated that all of the shares were offered by Arena at a price to the public of $5.50 per share.
Arena said that it received about $69.6 million gross proceeds from this offering, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by Arena.
Arena anticipates using the net proceeds from the offering for general corporate purposes, which may include expenses related to the commercialization of lorcaserin, if approved, as well as for research and development expenses, capital expenditures, working capital, and general and administrative expenses.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.